ArticleJournal of nephrology2025
Comparative validation of the Mayo Clinic imaging classification and PROPKD score for predicting ADPKD progression across diverse ethnic cohorts.
Article in Journal of nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Association of Kidney Volume With Patient-Reported Outcomes in ADPKD.Kidney international reports · 2026Article
- Evaluating gene variations in autosomal dominant polycystic kidney disease patients using whole exome sequencing and phenotype to genotype analysis.Renal failure · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAutosomal dominant polycystic kidney disease (ADPKD) is a common cause of end-stage kidney disease (ESKD). In this retrospective multicenter cohort study, we aimed to evaluate the concordance, sensitivity and specificity of the predictive abilities of the Mayo Clinic Imaging Class (MCIC) and Predicting Renal Outcome in Polycystic Kidney Disease (PROPKD) score for progression to ESKD.
methodsData for adult ADPKD patients of diverse ethnicities were obtained from 4 renal centers (Saint Louis, Kayseri, Bursa, Istanbul). The predictive value of MCIC and PROPKD was compared for progression to ESKD. ESKD was defined by the following criteria: (1) two consecutive estimated glomerular filtration rate (eGFR) < 15 ml/min/1.73m
resultsOne hundred eighty-seven ADPKD patients with PKD1 or PKD2 variants were included, with the majority identifying as White (93%), followed by Black (6%) and Hispanic (0.5%). The PROPKD score showed moderate ability (AUC = 0.702) to predict progression to ESKD, performing better in Black patients (AUC = 0.800) than in White patients (AUC = 0.764). However, the predictive accuracy declined (AUC = 0.644) when the PROPKD score was categorized into risk levels (low, intermediate, high). The MCIC showed lower ability (AUC = 0.578) to predict progression to ESKD than the PROPKD score. Using LASSO regularization and multivariable Cox regression, self-identified Black ethnicity [HR = 12.24 (95% CI: 3.19-46.94, p < 0.001)] and age at initial follow-up [HR = 1.05 (95% CI:1.01-1.09, p = 0.007)] emerged as significant predictors of progression to ESKD.
conclusionsThe PROPKD score appears to be a useful tool for predicting ADPKD progression across various ethnic groups, with self-identified Black ethnicity and age at initial follow-up emerging as key predictors of kidney failure.
Indexed as
Identifiers
40202714What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.